September 11, 2014. NCHR states that, after careful review of the data, we are skeptical about whether Liraglutide meets the standards of safety and efficacy that patients and consumers deserve.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at FDA on Nebivolol/Valsartan for Treating Hypertension
September 9, 2014. We share the FDA’s reservations about the clinical relevance of the small reductions in blood pressure. We question whether approving this combination drug will make a difference in patients’ health.
Read More »NCHR Testimony at the Nonprescription Drugs Advisory Commitee on OTC Antiseptics
September 3, 2014. We are all aware of the important role that OTC antiseptics play in reducing the risk of infection, particularly in the healthcare setting. That is why it is crucial to ensure that the ingredients in these products are as safe and effective as possible.
Read More »Patient, Consumer, and Public Health Coalition Comments on the Up-Classification of Flu Detection Tests
August 20, 2014. Members of the Patient, Consumer, and Public Health Coalition strongly support the up-classification of influenza detection devices. We support moving the devices from class I to class II with special controls and into a new device classification regulation (from 21 CFR 866.3330 to 21 CFR 866.3328). We agree with the FDA that “the accuracy of these devices has serious public health implications,” since influenza can cause serious illness and death.
Read More »NCHR Testimony at 2014 National Antimicrobial Resistance Monitoring System Scientific Meeting
August 13, 2014. We urge the participating agencies to ensure that NARMS receives the funding that it needs to maintain and build upon these vital efforts. Antibiotic resistant infections are estimated to cost the U.S. healthcare system between $21 and $34 billion dollars every year.
Read More »